Pneumococcal resistance 위험 인자가 있는 경우에 급성 세균성 부비동염의 치료

Pneumococcal resistance 위험 인자가 있는 경우에 고용량 아목시실린-클라블라네이트(2 g/125 mg extended-release tablets orally twice daily)를 사용합니다.

High-dose high dose amoxicillin-clavulanate (2 g/125 mg extended-release tablets orally twice daily) is appropriate initial therapy for patients who are at higher risk for pneumococcal resistance or poor outcomes (algorithm).

​

Risk factors for pneumococcal resistance in patients with acute bacterial rhinosinusitis

Living in geographic regions with rates of penicillin-nonsusceptible S. pneumonia exceeding 10%*

Age ≥65 years

Hospitalization in the last five days

Antibiotic use in the previous month

Immunocompromise

Multiple comorbidities (eg, diabetes or chronic cardiac, hepatic, or renal disease)

Severe infection (eg, evidence of systemic toxicity with temperature of ≥102°F, threat of suppurative complications)

* Local and regional histograms of bacterial resistance should be referenced to understand resistance trends in the local community.

​

REF. UpToDate 2019.06.18